Aimmune Therapeutics announced it will collaborate with Regeneron Pharmaceuticals and Sanofi to develop its experimental peanut allergy drug, according to a Reuters article.
The company will test the drug, AR101, in combination with Regeneron and Sanofi’s dupilumab in a mid-stage trial that is slated to start next year. The trial will be sponsored by Regeneron.
AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy, and dupilumab is a human monoclonal antibody that inhibits signaling of IL-4 and IL-13 cytokines, which are believed to be major drivers of Type 2 inflammation.
Currently, there are no approved treatments for peanut allergies.
Read the full story